Adverse Event Management & Monitoring

Adverse event (AE) classification is the foundation of systematic pharmacovigilance — the science of detecting, assessing, and preventing adverse effects of medications. For peptide therapy practitioners, understanding how to classify adverse events enables appropriate response calibration (is this a minor nuisance or a medical emergency?), proper reporting (which events require MedWatch reporting, which require pharmacy notification, which require urgent referral?), and communication with patients, other healthcare providers, and regulatory bodies (PMID 19487960).

The standard classification framework distinguishes: (1) Adverse events by severity — mild (causing awareness but not interfering with daily activities), moderate (affecting daily activities but not incapacitating), severe (incapacitating, requiring medical intervention or hospitalization), and life-threatening. The Common Terminology Criteria for Adverse Events (CTCAE), developed by the NCI for oncology trials, uses a 1-5 grade scale where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe but not life-threatening, Grade 4 = life-threatening, Grade 5 = death. Adopting this framework for peptide therapy documentation creates a standardized vocabulary compatible with regulatory reporting requirements.

(2) Adverse events by causality — definite (clear temporal relationship, consistent with known pharmacology, rechallenge positive), probable (plausible temporal relationship, no other cause identified), possible (temporal relationship exists but other causes not excluded), unlikely (another cause much more plausible), and unrelated. Causality assessment requires clinical judgment and should be documented in the medical record for each adverse event. A definite adverse event with semaglutide would be nausea beginning within hours of the first injection and resolving between doses — this matches the known mechanism and timing perfectly. A "possible" adverse event would be a headache two weeks after initiating ipamorelin — plausible but not mechanistically obvious.

(3) Expected versus unexpected adverse events — expected AEs are those consistent with the known pharmacological profile of the peptide (e.g., nausea with GLP-1 agonists, fluid retention with GH secretagogues, hyperpigmentation with bremelanotide). Unexpected AEs are those not previously described or inconsistent with the known pharmacology — these are of particular interest for regulatory reporting and require more thorough investigation and documentation. For investigational peptides (BPC-157, MOTS-c, humanin), any adverse event should be considered potentially unexpected given the limited human data, and the threshold for thorough documentation and reporting should be low.